Study identifier:D3560L00072
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
12-week, open-label, multi-center, prospective study evaluating the effect of individualizing starting doses of rosuvastatin according to baseline LDL (low density lipoprotein)-cholesterol levels on achieving cholesterol targets in type 2 diabetic patients
Type 2 Diabetes
Phase 4
No
Rosuvastatin
All
598
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Rosuvastatin 1 titrated | Drug: Rosuvastatin Oral Other Name: Crestor |
Experimental: Rosuvastatin 2 Non-titrated | Drug: Rosuvastatin Oral Other Name: Crestor |